Immune therapy which targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) mechanism of tumor immune evasion is a promising field of ovarian cancer therapy. This evidence concerns the gene PDCD1 and ovarian cancer.